Could these FTSE 100 giants boost your portfolio higher?

Should you be buying these three FTSE 100 (INDEXFTSE: UKX) stocks for their income potential?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 100 (INDEXFTSE: UKX) stocks can provide great returns for investors. Through income and growth the stocks can be a stable way to get rich slowly. 

Commodity giant

Glencore (LSE: GLEN) has been under the spotlight for over a year now. Commodity prices across the board fell sharply, which dragged the share price of Glencore down to all-time lows. However, since then the company has done a lot counter criticism of its business and it has come a long way since City analysts were saying it could go to zero. Since 1 January the share price has climbed 125% and analysts are now tagging the stock with price targets over 250p. The company has looked at the issue of its debt pile and divested a number of assets to pay off debt. I believe that the major mining company could be a good way to ride strengthening commodity prices that many expect in the next few years. The stock is coming from a very low price so it could see an explosive price rise soon. 

Defensive pharma

GlaxoSmithKline (LSE: GSK) is a favorite of UK income fund managers and quite rightly so. It holds great defensive qualities and I believe it has less risk than its FTSE 100 peer AstraZeneca. Glaxo shares are currently yielding over 4%, which is a decent income considering we live in a world of low interest rates. For income investors this looks like a top stock to own for its dividend and growth potential. The pipeline of new drugs that Glaxo has is very encouraging and the company believes there could be multiple blockbuster drugs on the way. This pipeline will add to profitability for the firm. While currently the shares are trading on 17 times forward price-to-earnings, Glaxo looks set to reap the rewards of its R&D success and I think the shares look cheap. 

UK housebuilding play

Persimmon (LSE: PSN) is about to become a great income stock due to the huge dividend scheme the company is about to begin. The shares are on a yield of over 5% and have nearly recovered since the Brexit vote shock. The UK has a fundamental housing shortage, which was addressed by Chancellor Philip Hammond this week. When setting out his new £5bn housing fund he said “my message today is clear: it’s time to get building”. This fund is for small businesses to build 25,000 homes by 2020 and 225,000 in the longer term. This is a clear indication that the housebuilding sector in the UK has a lot of work to do. Persimmon is a great way to play housebuilding in the UK and receive some income at the same time. 

I believe that these three giants will provide investors with good capital growth over the next few years and should outperform the wider market. In the case of Glaxo and Persimmon, investors will receive some chunky dividend payouts too. 

Jack Dingwall has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Black woman using a debit card at an ATM to withdraw money
Investing Articles

Meet the FTSE 100’s newest bank stock

This FTSE 250 stock has skyrocketed nearly 900% over the past 60 months, earning it a place in the prestigious…

Read more »

Investing Articles

See what £10,000 invested in Shell shares 1 month ago is worth now

Harvey Jones looks at how Shell shares have fared over the past month and more importantly, what the long-term outlook…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Growth Shares

At its lowest level since July, here’s why I think the IAG share price is dead cheap

Jon Smith explains why the IAG share price has fallen over the past week but talks through the reasons why…

Read more »

Picture of an easyJet plane taking off.
Investing Articles

Will the easyJet share price rise 43% or 97% by this time next year?

City analysts believe easyJet's share price might almost double over the next year. Royston Wild considers the outlook for the…

Read more »

Female student sitting at the steps and using laptop
Investing Articles

More great news for Rolls-Royce shares!

Rolls-Royce shares got a boost this week after some intriguing developments in the process of creating Europe's new fighter aircraft.

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Persimmon’s share price surges 7% on double boost! Can it keep rising?

Persimmon's share price is surging, up 11% at one point earlier on Tuesday. Could this be the start of a…

Read more »

This way, That way, The other way - pointing in different directions
Investing Articles

What on earth’s happening to the Greggs share price?

Harvey Jones says Greggs’ share price has shown surprising resilience in the recent stock market turmoil, but the FTSE 250…

Read more »

Mature black woman at home texting on her cell phone while sitting on the couch
Investing Articles

Barclays shares are down 18%. Time to consider buying?

Barclays’ shares have plummeted in recent weeks. Edward Sheldon looks at what’s going on and provides his view on the…

Read more »